subscribeSubscribe
Teva`s AJOVY® Effective, Safe For Migraine Prevention In China

Teva`s AJOVY® Effective, Safe For Migraine Prevention In China
BUSINESSWIRE
11 Apr 2024
Share Share
New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks

New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks
BUSINESSWIRE
06 Dec 2023
Share Share
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks
BUSINESSWIRE
17 Oct 2023
Share Share
US judge overturns Eli Lilly`s $176.5 million loss in Teva patent case

US judge overturns Eli Lilly`s $176.5 million loss in Teva patent case
REUTERS
27 Sep 2023
Share Share
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab)

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab)
BUSINESSWIRE
30 Jun 2023
Share Share
Teva to Present Data at the 2023 Scientific Meeting Demonstrating AJOVY

Teva to Present Data at the 2023 Scientific Meeting Demonstrating AJOVY
BUSINESSWIRE
15 Jun 2023
Share Share
Teva leans on Ajovy and Austedo as revenues sink

Teva leans on Ajovy and Austedo as revenues sink
Zoey Becker FIERCE PHARMA
08 Feb 2023
Share Share
Teva walks away from PhRMA after similar move by AbbVie

Teva walks away from PhRMA after similar move by AbbVie
Fraiser Kansteiner FIERCE PHARMA
04 Feb 2023
Share Share
Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY

Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY
PRESS RELEASE
18 Nov 2022
Share Share
Studies Show Effectiveness of AJOVY for Treatment of Migraine

Studies Show Effectiveness of AJOVY for Treatment of Migraine
BUSINESSWIRE
08 Sep 2022
Share Share